The U.S. Department of Health and Human Services unveiled a plan to speed up early-stage drug development, including a push to reduce the timeline to first-in-human testing by 6 to 12 months. The initiative targets earlier experimental drug development and includes changes to how Investigational New Drug (IND) applications are prepared. HHS’ blueprint outlines efforts to specify what data are needed before IND filing, aiming to cut unnecessary documentation burdens. It also calls for more flexible trial protocol updates and introduces a pilot structure that allows developers to consult with a network of research institutions while preparing IND packages. A separate component emphasizes a “rolling submission” concept to support more timely FDA guidance during early development planning. The package also examines ways to expand clinical trial enrollment in the U.S., including potential stipend mechanisms for participants. The stated motivation is to preserve U.S. competitiveness as trial initiation timelines are increasingly pressured by faster-moving jurisdictions, particularly China.